The global targeted DNA RNA sequencing market size is expected to reach USD 34.56 billion in 2030 and is projected to grow at a CAGR of 19.4% from 2024 to 2030. Targeted Sequencing has emerged as a key technology in life science research by enabling examination of a specific region of interest while keeping the seq. cost as well as the complexity of data under manageable limits.

This approach enhances sequencing depth by allowing the evaluation of specific coding regions within genes or specific genes, which are known to harbor mutations for disease pathogenesis. Several research projects have employed this technology to avoid wastage of information and extra cost and study only relevant genes. The number of such projects continues to grow, consequently driving the market.

Innovations to address the pitfalls of targeted enrichment methods are anticipated to enhance the usage rate of this technology throughout the forecast period. Moreover, with a decrease in seq-cost and improvement in informatics, targeted methods have become more accessible for use in clinical settings than ever.

Access the Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Product (NGS), By Workflow (Pre-sequencing), By Application, By Technology, By Type, By End Use, And Segment Forecasts, 2024 - 2030

Targeted DNA RNA Sequencing Market Report Highlights

·        Rapid advancements in NGS and its ancillary protocols can be attributed to the growth of this segment.

·        Out of all the NGS-based targeted methods, exome-seq held the largest share.

·        This can be attributed to the fact that though it accounts for less than 2% of the genome, it contains 85% of the known disease-relevant variants.

·        Entire targeted approach is broken down into presequencing, sequence determination, and data analysis.

·        Being the most crucial step, sequencing accounted for the largest share.

·        This space has revolutionized various applications of life sciences, including human biomedical research, plant & animal sciences, drug discovery, and others.

·        Out of all, human biomedical research is estimated to be the largest application of this space due to its high usage in studying disease pathogenesis.

·        The targeted DNA/RNA sequencing market is bifurcated into DNA-seq and RNA-seq, based on the sample type.

·        DNA-sequencing has been estimated to generate higher revenue over its counterpart segment. This can be attributed to the presence of a wide range of products and kits for DNA-seq.

·        As per end use, academic research is estimated to be the largest segment owing to the increase in seq-based projects at universities and other academic centers.

·        North America held the largest share owing to the presence of effective regulations pertaining to approval of genetic tests and bioinformatics tools.

·        Moreover, the U.S. is observed to have the highest number of installed sequencers, which in turn, has contributed to the large share of the North America regional market.

·        Asia Pacific is expected to emerge as the fastest growing regional market.

·        Rise in genome-based projects coupled with constant GDP growth in Asian countries is expected to drive the Asia Pacific market.

Key Targeted DNA RNA Sequencing Company Insights

Some key companies in the global targeted DNA RNA sequencing market include Illumina, F. Hoffman La-Roche Ltd, QIAGEN, Bio-Rad Laboratories, and others. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players undertake several strategic initiatives, such as mergers, acquisitions, and partnerships with other major companies.

Illumina is among the world’s foremost makers of genomic equipment including DNA sequencing and microarray technology. Their products assist researchers and healthcare providers with information that can be used to diagnose diseases, develop individualized treatments, and progress various scientific disciplines related to genetics.

Roche is a leading healthcare company, dedicated to research and innovation in pharmaceutical and diagnostic products. They own leading clinical products in oncology, immunology, and diagnostic products for personalized medicine.

Order your free sample copy of “Targeted DNA RNA Sequencing Market Report 2024 - 2030, published by Grand View Research

Key Targeted DNA RNA Sequencing Companies:

The following are the leading companies in the targeted DNA RNA sequencing market. These companies collectively hold the largest market share and dictate industry trends.

·        Illumina

·        F. Hoffman-La Roche Ltd.

·        QIAGEN

·        Thermo Fisher Scientific, Inc.

·        Bio-Rad Laboratories, Inc.

·        Oxford Nanopore Technologies

·        PierianDx

·        Genomatix GmbH

·        DNASTAR, Inc.

·        Perkin Elmer, Inc.

Recent Developments

·        In June 2024, Bio-Rad launched a new ddSEQ Single-Cell 3' RNA-Seq Kit to support single-cell gene expression research. This kit enables researchers to affordably and rapidly analyze gene expression on the single-cell resolution. It is anticipated that this technology will help in the research of oncology, immunology, and more.

·        In May 2024, a new paper was published in Genomic Medicine highlighting global efforts to increase access to genome sequencing for diagnosing rare genetic disorders and focusing on its potential to improve diagnosis speed and reduce healthcare costs. The Medical Genome Initiative calls for broader insurance coverage, reduced administrative barriers, and increased clinician education to support the widespread adoption of genome sequencing.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com